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Abstract
Backgroud: The emergence and ongoing spread of antimicrobial-resistant bacteria is a major public health threat.
Infections caused by antimicrobial-resistant bacteria are associated with substantially higher rates of morbidity and
mortality compared to infections caused by antimicrobial-susceptible bacteria. The emergence and spread of these bacteria
is complex and requires incorporating numerous interrelated factors which clinical studies cannot adequately address.
Methods/Principal Findings: A model is created which incorporates several key factors contributing to the emergence and
spread of resistant bacteria including the effects of the immune system, acquisition of resistance genes and antimicrobial
exposure. The model identifies key strategies which would limit the emergence of antimicrobial-resistant bacterial strains.
Specifically, the simulations show that early initiation of antimicrobial therapy and combination therapy with two antibiotics
prevents the emergence of resistant bacteria, whereas shorter courses of therapy and sequential administration of
antibiotics promote the emergence of resistant strains.
Conclusions/Significance: The principal findings suggest that (i) shorter lengths of antibiotic therapy and early interruption
of antibiotic therapy provide an advantage for the resistant strains, (ii) combination therapy with two antibiotics prevents
the emergence of resistance strains in contrast to sequential antibiotic therapy, and (iii) early initiation of antibiotics is
among the most important factors preventing the emergence of resistant strains. These findings provide new insights into
strategies aimed at optimizing the administration of antimicrobials for the treatment of infections and the prevention of the
emergence of antimicrobial resistance.
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Introduction
Antimicrobial resistance among bacteria has become a
worldwide public health threat [1–3]. Despite substantial inter-
ventions aimed at preventing the emergence and spread of
antimicrobial-resistant bacteria, the rates continue to rise rapidly
[4]. The geographic locations affected by antimicrobial resistance
are mounting [2]. The economic impact of antimicrobial
resistance is substantial [1]. Infections caused by these antimicro-
bial-resistant bacteria are associated with substantially higher
mortality rates, longer hospital stays and greater hospital costs,
compared to infections caused by antimicrobial-susceptible
bacteria [5,6]. In 1998, it was estimated that the annual cost of
antimicrobial resistance in hospitals due to Staphylococcus aureus was
already $122 million and of nosocomial infections was $4.5 billion
[1,7]. A recent estimate showed that there were 18,650 deaths in
patients with invasive methicillin-resistant S. aureus in the United
Sates in 2005, exceeding the total number of deaths due to HIV/
AIDS in the same year [8].
In the last decade, mathematical models have been increasingly
used as tools to identify factors responsible for observed patterns of
antimicrobial resistance, to predict the effect of various factors on
the prevalence of antimicrobial resistance, and to help design
effective control and intervention programs [9–16]. We also refer
to the surveys on this topic [14,15,17–19]. Most of these studies
have used differential equations models, which aggregate patient
and health-care worker populations into compartments such as
colonized or uncolonized patients and contaminated or uncon-
taminated health-care workers. Interventions proposed by these
studies have focused on reducing the transmission of antimicro-
bial-resistant bacteria between patients thereby preventing de novo
acquisition. Antimicrobial treatments have also been evaluated in
some of these studies. For example, Bonhoeffer et al. [10]
considered two models for treatment and resistance with a single
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antibiotic is employed, sequential (cycling) use of different
antibiotics is not as good as that with a combination of antibiotics.
Bergstrom et al. [11] further developed a mathematical model to
study the efficacy of cycling program and found that cycling is
unlikely to reduce the spread of antimicrobial resistance. Se also
[49,50].
One of the main limitations in providing guidance with
antibiotic administration is the paucity of data regarding optimal
duration of therapy and patterns of use which would reduce the
emergence and spread of resistant bacteria. This lack of data is due
to the fact that patient-oriented clinical studies cannot fully address
the multitude of factors that are involved in the treatment of
infections, the emergence of resistance and the role of the immune
system in eradicating the infection. D’Agata et al. [12] integrated
an individual-based model and a deterministic model to provide a
quantitative analysis of the emergence and spread of antimicrobial
resistant bacteria and demonstrated that early initiation of
treatment and minimization of its duration mitigates antimicrobial
resistance epidemics in hospitals.
Mathematical models have also developed to study pharmaco-
dynamics of various antimicrobial therapies [20–23]. Lipsitch and
Levin [22] presented a simple mathematical model of pharmaco-
kinetics and bacterial population dynamics that is designed to
address the problem of suppressing the emergence of resistance
during treatment. They restricted their consideration to treatment
with bactericidal antibiotics and the evaluation of resistance by
mutation. Via mathematical modelling and computer simulations,
the effect of mutation in antimicrobial resistance has further
investigated by Levin and Rozen [23] who showed non-inherited
resistance could extend the duration of antimicrobial treatment,
cause treatment failure and promote the generation and ascent of
inherited resistance in treated patients.
Bacteria can also develop antimicrobial resistance through the
acquisition of new genetic material from other resistant organisms,
such as horizontal gene transfer [24,25]. The widespread
dissemination of antimicrobial resistance genes are the results of
improper and excessive administration of antibiotics, combined
with the ready bacterial ability to transfer antimicrobial resistance
genes through plasmids and transposons and the presence of large
transfer communities such as hospitals [24]. Compared to the
mathematical modelling on population dynamics of the antimi-
crobial resistance bacteria, there are few models describing the
horizontal transfer of antimicrobial resistance genes [24], which
could help better understand the mechanisms of antimicrobial
resistance in bacteria and provide more effective treatment.
Multidrug-resistant bacteria can colonize specific sites in the
host and evade immune surveillance [26]. The nature of the host
immune response to multidrug-resistant bacterial infection is
complex. To the best of our knowledge, the combined effect of
immune response, horizontal gene transfer and antibiotic
treatment has not been modelled and explored. In this article,
we develop a new mathematical model which incorporates three
key aspects in the emergence of resistance caused by antibiotic
exposure: the response of the host’s immune system, horizontal
transfer of resistance genes and patterns of antibiotic treatment
regimens. Specifically, we want to propose a model for the
bacterial population and study the within-host dynamics that
would provide critical information regarding the optimal regimens
for antibiotics administration in the treatment of infections in
order to prevent the emergence of antimicrobial resistant bacteria.
By mathematical modelling and numerical simulations, we
demonstrate the importance and significance of the necessary
length of antimicrobial treatment, the early initiation of treatment,
and the combination of antibiotics in preventing antimicrobial
resistant bacterial infections in treated patients.
Table 1. List of Parameters and their Values.
Symbol Interpretation Value Units References
l Growth rate of bacteria 2.7726 (without treatment)
(i) day
21 [27,28,29]
2.7726 21.9 with treatment A (sensitive to A)
2.7726 22.1 with treatment B (sensitive to B)
d Division rate of bacteria 2.7726 day
21 This study
(ii)
m Mortality rate of sensitive bacteria 0 without treatment day
21 This study
1.9 with treatment A (for sensitive to A) day
21
2.1 with treatment B (for sensitive to B)
kl k is the carrying capacity of bacteria 10
15/2.7726
(iii) This study
c Killing rate of Phagocytes 33.6038
(iii) day
21 This study
P Total Number of Phagocytes 332711
(iii) This study
t Recombination rate 10
23 day
21 [41,43]
p Probability that a plasmid is lost during the division without antibiotic pressure 0.4
(iv) This study
(i)In the work from [31], the E. coli generation time in vivo in the gastrointestinal tract was approximately 60 min (l=16.6622 day
21) and was quasi-static in the lumen
content. However, the authors state that these results are specific to their experimental conditions, without competition with other bacteria. In our model, we chose a
longer generation time based on (a) other studies [27–29]; and (b) the relevance of our simulations. Indeed, if l is set at 16.6622 day
21, the bacterial growth was at a
rate that antibiotic therapy was totally inefficient, even for susceptible bacteria.
(ii)In this study we assume that the mortality rate of bacteria in absence of antibiotics is negligible.
(iii)These parameters have been adjusted to maintain an infection threshold of 10
6 bacteria [32] and a rate of invasion comparable to previous studies [12].
(iv)The probability that a plasmid is lost during the division without antibiotic pressure depends on the bacteria and plasmid size. According to several studies, we chose
an average parameter representative of E. coli and the common size of plasmid bearing resistance genes [33–36]. This probability may vary from 0 to 1 among 50
generations cell. In this model, this parameter was set at a value to provide adequate simulations.
doi:10.1371/journal.pone.0004036.t001
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(A) Model with immune response and single antibiotic
treatment
We first present an ideal case of a homogenous bacterial
population within a host treated by an antimicrobial agent. Since a
growing bacterial population will eventually saturate due to the
limitation of nutrients and space, we use the logistic growth to
describe the population dynamics of the bacteria. Also assume that
the bacteria are killed by the antimicrobial agent at a constant rate
proportional to the density of the bacteria population.
Let B(t) be the number of bacteria at time t. Let d (day
21) be the
division rate and m (day
21) the mortality rate due to antibiotic
treatment. So l=d2m is net growth rate and lk is the carrying
capacity of the bacteria, the term {Bt ðÞ
2
.
lk describes the
limitation of space and food available to the bacteria. The
bacterium Escherichia coli is chosen for this model since baseline
parameters pertaining to its biology are available from the
literature. For E. coli, the average in vivo doubling time (AV) is
0.4 day, based on data from several studies [27,28,29]. The growth
rate is l=ln2/ AV=2.7726 day
21. The maximum number is set
at lk~1015 bacteria [12]. Thus, k~1015 
2:7726.
Now we consider the response of the host’s immune system to
the invading bacteria. The innate immunity is characterised by a
rapid action of the host’s effectors cells including leukocytes, which
will limit the multiplication of bacteria and destroy them. Assume
that the killing rate of bacteria by leukocytes satisfies the Monod
function [21,30]. In our model, the minimal infecting dose, or
threshold of bacteria required to overcome the immune system,
will be addressed. This value implies that above the threshold, the
immune response is ineffective against bacterial growth and the
infection progresses.
For the immune system to be ineffective and the infection to
progress, the bacterial population need to be above the minimal
infecting dose, or threshold, which is related to the number of
phagocytes. Indeed, we can consider the following equation:
B’ t ðÞ ~ lBt ðÞ
|ﬄﬄ{zﬄﬄ}
Division
and
Mortality
{Bt ðÞ
2
.
k
|ﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄ}
Limitation
of
Ressources
{c
P
PzBt ðÞ
Bt ðÞ
|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
Immune
Response
,
ð1Þ
where P is the equilibrium number of activated phagocytes, and c
(day
21) is the maximal killing rate of bacteria by activated
phagocytes. We assume that the number of phagocytes remains
constant. The main consequence of this assumption is that the
threshold of invasion and the threshold of bacterial eradication are
the same [21]. For other values see Table 1.
Model (1) has at most three non-negative equilibria.   B B0~0 is
always an equilibrium, which is stable if l=d2m.0 and unstable
if l=d2m,0. There eventually exist two other equilibria which
are solutions of the quadratic equation B2{ kl{P ðÞ Bz
kP c{l ðÞ ~0. It has two roots   B B+~ kl{P ðÞ +
ﬃﬃﬃﬃ
D
p    .
2 if
D : ~ kl{P ðÞ
2{4kP c{l ðÞ w0, where   B B{ corresponds to the
invasion threshold and   B Bz corresponds to the maximal bacterial
load. In practice, we fix   B B{~106 [32] and   B Bz~1015 corre-
sponding to the experimental value obtained in previous studies
[12]. Notice that with parameter values in Table 1,   B B{ is unstable
Figure 1. Simulations of Model (1) on the duration of antimicrobial treatment and its effects on infection progression. The initial
value is chosen between 10
6 and 10
15, so the solution increases initially. The green line represents the threshold of bacterial load above which an
infection develops. Below this threshold, the phagocyte density is sufficient to prevent the progression to infection. (a) Treatment starts at the 4
th day
after an infection and lasts for 9 days. The bacterial load decreases to below the threshold and the infection is prevented. (b) Treatment starts at the
4
th day after an infection and lasts for only 6 days. The bacterial load decreases to close to the threshold, but stays above it and increases again. The
infection becomes more progressive.
doi:10.1371/journal.pone.0004036.g001
Antimicrobial-Resistance
PLoS ONE | www.plosone.org 3 December 2008 | Volume 3 | Issue 12 | e4036and   B Bz is stable. Thus, the asymptotic behavior of solutions of
Model (A) depends on the location of the initial value. If the initial
bacterial load is between 10
6 and 10
15, then the solution will
increase and approach   B Bz as time involves. However, treatment
can change the dynamics (see simulations in Results).
(B) Model with resistant strains to one antibiotic through
horizontal gene transfer
Antimicrobial resistance among bacteria can be intrinsic or
acquired either through de novo mutations or via the acquisition of
antimicrobial-resistance genes [25]. The latter occurs through
horizontal gene transfer of mobile genetic elements including
plasmids, integrons and transposons
37. Acquisition of resistance
genes is among the main mechanism of antimicrobial resistance
among E. coli isolates [38–40].
Let BS t ðÞand BR(t) denote the population levels of antibiotic-
sensitive (plasmid free) and antibiotic-resistant (plasmid bearing)
bacteria at time t, respectively, so that Bt ðÞ ~BS t ðÞ zBR t ðÞis the
total bacterial load in a host. Thus, BS t ðÞ =Bt ðÞis the fraction of
bacteria that are antibiotic-sensitive and BR t ðÞ =Bt ðÞ is the
fraction of bacteria that are antibiotic-resistant. Let t be the
recombination rate (i.e. horizontal gene transfer rate) of plasmid
free and plasmid bearing to plasmid bearing. Then
tBS t ðÞ BR t ðÞ =Bt ðÞ represents the recombination process. Let p
be the probability that a plasmid is lost, which varies after 50
generations from 0, 40 or 100% [33–35] and depends on the
type of plasmid, its stability and copy number, and the presence
of the antibiotic pressure. In practice this leads to the estimation
of dR
p
2 as the reversion rate of plasmid bearing to plasmid free,
where dR is the division rate of the antibiotic-resistant bacteria.
Let dS be the division rate of the antibiotic-sensitive bacteria, mS
and mR be the mortality rates of plasmid free and plasmid
bearing bacteria, respectively.
Extending the model of Webb et al. [16] to include the immune
response, we obtain the following:
BS
’ t ðÞ ~{t
BS t ðÞ BR t ðÞ
Bt ðÞ
z dS{mS ðÞ BS t ðÞ zdR
p
2
BR t ðÞ {
Bt ðÞ
k
BS t ðÞ {c
P
PzBt ðÞ
BS t ðÞ
BR
’ t ðÞ ~t
BS t ðÞ BR t ðÞ
Bt ðÞ
z dR 1{
p
2
  
{mR
  
BR t ðÞ {
Bt ðÞ
k
BR t ðÞ {c
P
PzBt ðÞ
BR t ðÞ
8
> > > > > > > > > > > > > <
> > > > > > > > > > > > > :
ð2Þ
The rate of horizontal gene transfer occurs at a rate ranging from
10
21 to 10
26 genes per cell per generation [41–43]. In this model,
we assume that gene transfer occurs at a rate of 10
23/day. Since
plasmid-bearing bacteria have a longer generation time than
plasmid-free bacteria, we assumed a 40% increase in generation
time among the plasmid-bearing bacteria [36,44]. In the absence
of antibiotic pressure, plasmids carrying antimicrobial resistance
genes are lost to minimize costs associated with replication and
conservation, as shown in several studies [33–36]. In our model,
plasmid loss during bacterial replication is set at 10
25 per cell and
per generation [36,45,46]. In absence of antibiotics, we can
assume that dS{mS ðÞ ~ dR{mR ðÞ . In this case B(t) satisfies Model
(1). So we observe that BS t ðÞ zBR t ðÞ ~  B Bz.
Figure 2. Simulations of Model (1) on the initiation of an antimicrobial therapy and infection progression. (a) Treatment starts at the 1
st
day after an infection and lasts for 9 days. The bacterial load decreases to below the threshold and the infection is prevented. (b) Treatment starts at
the 3
rd day after an infection and lasts for 9 days. The bacterial load decreases slightly, but stays above the threshold and increases even during the
treatment.
doi:10.1371/journal.pone.0004036.g002
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B 0 ðÞ w  B B{ and (BS t ðÞ , BR(t)) converges to (  B BS,  B BR) as time t
increases, where   B BS~dRp  B Bz=2 and   B BR~  B Bz 1{dRp= 2t ðÞ ðÞ .
The proportion of antibiotic-susceptible and -resistant bacteria
can therefore be quantified in function of the parameter in absence
of antibiotics.
(C) Model with different antibiotic treatments and
multidrug-resistant (MDR) strains
Finally we consider the situation when the bacteria are
multidrug-resistant. We will model different antibiotic treatments
and study the combined treatment regimens. Denote
BS(t)–the number of antibiotic-sensitive (plasmid-free)
bacteria at time t
BA(t)–the number of bacteria resistant to antibiotic A but
not resistant to antibiotic B (i.e. bacteria bearing only
plasmid A)
BB(t)–the number of bacteria resistant to antibiotic B but
not resistant to antibiotic A (i.e. bacteria bearing only
plasmid B)
BAB(t)–the number of bacteria resistant to both antibiotics
A and B (i.e. bacteria bearing both plasmids A and B).
Considering exposure to two antibiotics and generalizing the
Model (2) which includes the effect of the saturation due to food or
space limitation, and the effect of immune system, we have the
following model:
BS
’ t ðÞ ~{t
BS t ðÞBA t ðÞ zBB t ðÞ zBAB t ðÞ ðÞ
Bt ðÞ
z dS{mS ðÞ BS t ðÞ
zdA
p
2
BA t ðÞ zdB
p
2
BB t ðÞ zdAB
p2
2
BAB t ðÞ {
Bt ðÞ
k
Bs t ðÞ
{c
P
PzBt ðÞ
BS t ðÞ
BA
’ t ðÞ ~t
BS t ðÞ BA t ðÞ
Bt ðÞ
{t
BA t ðÞBB t ðÞ zBAB t ðÞ ðÞ
Bt ðÞ
z dA 1{
p
2
  
{mA
  
BA t ðÞ zdAB
p
4
BAB t ðÞ
{
Bt ðÞ
k
BA t ðÞ {c
P
PzBt ðÞ
BA t ðÞ
BB
’ t ðÞ ~t
BS t ðÞ BB t ðÞ
Bt ðÞ
{t
BB t ðÞBA t ðÞ zBAB t ðÞ ðÞ
Bt ðÞ
z dB 1{
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{mB
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p
4
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BS t ðÞ BAB t ðÞ
Bt ðÞ
zt
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ð3Þ
To simplify, we will assume that dS~dA~dB~dAB~2:7726=day
and the mortality rates are shown in Table 1.
Figure 3. Simulations of Model (2) on the interruption of treatment and infection progression. (a) Treatment is interrupted for 1 day at
day 3 and continues for the rest of the 9-day therapy. The bacterial load does not change much and increases afterward, the infection is progressive.
(b) Treatment is interrupted for 1 day at day 5 and continues for the rest of the 9-day therapy. The bacterial load decreases steadily and the infection
can be prevented.
doi:10.1371/journal.pone.0004036.g003
ð3Þ
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By carrying out numerical simulations of Models (1)–(3), we
study the impact of several factors, such as the immune response,
duration of antimicrobial therapy, initiation and interruption of
treatment, delay and sequential antimicrobial regimens, and
combination of antimicrobial therapies, on the progress of an
infection within a host. Note that in all simulations, the initial
values are chosen near the equilibrium values of these models.
(A) Immune system response and duration of
antimicrobial therapy
The first simulation (Model (1)) demonstrates the importance of
longer antimicrobial therapies required to prevent the progression
of an infection. When the bacterial load is below the minimal
infecting dose, the immune system is effective in killing bacteria
and the patient does not develop an infection. When the duration
of an antimicrobial therapy is for 9 days, the bacterial load is
reduced below the threshold and progression of the infection is
prevented. However, a shorter antimicrobial therapy of 6-day
courses does not reduce the bacterial load to below the threshold
and therefore an infection is not prevented (Figure 1).
(B) Initiation and interruption of treatment and resistant
strains to one antibiotic
The second simulation (Model (2)) addresses the issue of the
importance of the timing of antibiotic initiation in the progression
to an infection. The model includes the susceptible strain and a
strain that is resistant to antibiotic A. Antibiotics are administered
for a total of 9 days to optimize the duration of therapy, as shown
in Figure 1.
In Figure 2(a), the treatment starts at the first day of an infection
and in Figure 2(b), treatment is delayed and starts at the third day
of the infection. The treatment occurs with antibiotic A which is
ineffective against the resistant strain A. The simulations show that
if the initiation of a therapy is delayed the infection will progress. If
the antimicrobial therapy starts early, the infection can be treated
successfully, with both the susceptible and resistant strains.
The third simulation (Model (2)) addresses the issue of treatment
interruption and its impact on the progression of an infection. The
importance of initiating appropriate antibiotic therapy at the start
of infection is addressed in these simulations. In both Figures 3(a)
and 3(b) the treatment duration is for 9 days, but in Figure 3(a) the
treatment is interrupted for one day at day 3 and in Figure 3(b) the
interruption occurs at day 5. These simulations demonstrate that
early interruption of therapy results in the progression of an
infection with the resistant strain since the bacterial load of the
resistant strain exceeds the threshold of the minimum infecting
dose prior to treatment interruption.
We assume that the patient is harbouring a sensitive strain
(AsBs) and a strain that is resistant to antibiotic A but susceptible to
antibiotic B (ArBs). The effects of varying treatment sequences
with antibiotics A and B are simulated in Figure 4. Treatment with
antibiotic A is ineffective and the infection progresses, but
subsequent treatment with antibiotic B is effective in eradicating
the infection (Figure 4(a)). Concurrent therapy with antibiotics A
and B is more effective as the patient is treated with an effective
antibiotic against ArBs (Figure 4(b)).
(C) Delay and sequential antibiotic regimens on the
emergence of MDR strains
The impact of early initiation of therapy is addressed in the final
model (Model (3)) for treating two-drug resistant strains, since this
Figure 4. Simulations of Model (3) on multiple antibiotic therapies. In both simulations, treatment starts at the 4
th day after the infection and
lasts for 9 days. (a) If antibiotic A fails in the first therapy, then a second treatment with antibiotic B has to be administrated to prevent the infection.
(b) A combination of both antibiotics A and B can bring the bacterial level below the threshold and the infection can be prevented.
doi:10.1371/journal.pone.0004036.g004
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strain (Figure 2(a)). We assume that the patient is colonized with
three E. coli populations: a strain that is sensitive to both antibiotics
A and B (AsBs), a second strain that is sensitive to antibiotic A and
resistant to antibiotic B (AsBr), and a third strain which is resistant
to antibiotic B and sensitive to antibiotic A (AsBr). The impact of
concurrent or sequential therapies with antibiotics A and B and its
effect on the emergence of the two-drug resistant strains (ArBr) is
assessed.
We consider two scenarios: (i) The patient is treated with the
antibiotic A and than immediately with the antibiotic B, followed
by both antibiotics simultaneously (Figure 5(a)). (ii) Treatment
starts at the first day after the infection (Figure 5(b)). Simulations
demonstrate that early initiation of therapy, on day 1, can
eliminate the two-drug resistant strain ArBr irrespective of the
sequence of antibiotic therapies (Figure 5(b)). In this scenario, the
bacterial load of ArBr always remains below threshold. Thus, early
initiation of therapy and combined antimicrobial therapy are the
key measures to prevent and control infections with multi-drug
resistant strains.
To further simulate the early initiation of therapy and the effect
of combined therapy, in Figure 6(a) the patient is treated on the 3
rd
day after infection with both antibiotics A and B simultaneously.
In Figure 6(b) the patient is treated on the 10
th day after infection
with both antibiotics A and B simultaneously.
In these simulations (Figures 5 and 6), the antibiotic regimens
that eradicate the infection and eliminate the resistant strains are
therapies using antibiotics A and B simultaneously. In Figure 5(b)
and Figure 6, as opposed to Figure 5(a), the bacterial loads of AsBr
and ArBs decrease during therapy with antibiotic A and B,
respectively. The decrease in bacterial quantity diminishes the rate
of horizontal gene transfer, thereby preventing the emergence of
ArBr, despite ineffective therapy against two-drug resistant strain.
The efficacy of initiating therapy with both antibiotics simulta-
neously is persistent even if therapy is delayed (Figure 6(a)). The
optimal regimen in treating the two-drug resistant strains is
demonstrated in Figure 6(b): early treatment with a combination
of two antibiotics.
Discussion
Antimicrobial exposure is central to the emergence and spread
of antimicrobial-resistant bacteria. We have presented a model
delineating the interrelated factors of antimicrobial therapy, the
immune system and resistance gene transfer, and their effect on
the emergence of antimicrobial-resistant bacterial strains. The
model delineates novel findings with regards to the timing and
sequence of antibiotic therapy in preventing the emergence of
resistant strains. First, the model shows that shorter lengths of
antibiotic therapy and early interruption of antibiotic therapy
provide an advantage for the resistant strains and result in
infections caused by these resistant bacteria to progress. Second,
the model outlines the optimal antibiotic regimens which prevent
the progression of infection with a resistant strain. Our model
demonstrates that combination therapy with two antibiotics
prevents treatment failure and the emergence of resistant strains,
as opposed to sequential therapy. Third, the model shows that a
delay in the start of therapy is one of the key factors in promoting
the rapid rise in resistant strains. The early timing is even more
important than the type of antibiotic regimen since early initiation
of antimicrobials will prevent emergence of resistance regardless of
whether antibiotics are administered sequentially or concurrently.
Figure 5. Simulations of Model (3) on sequential treatment with antibiotics A and B. (a) Treatment with antibiotic A starts at the 3
rd day
after the infection and lasts for 10 days, right after that antibiotic B is administrated for 10 days, and at the 40
th day both antibiotics A and B are used
for 10 days. (b) Same therapies except that the first treatment starts at the 1
st day after the infection.
doi:10.1371/journal.pone.0004036.g005
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D’Agata et al. [12] also demonstrated that early initiation of
therapy is key to preventing the spread of antibiotic-resistant
bacteria within a hospital setting.
Population-level models quantifying the factors promoting the
spread of resistant bacteria have been instrumental in identifying
the preventive strategies most effective at decreasing cross-
transmission between patients [9–19]. These models have shown
the impact of overall antimicrobial exposure on the spread of
resistant bacteria. In our individual-level model, we extend the
analysis of antimicrobial exposure and treatment regimen to
further our understanding of the type and sequence of antimicro-
bial exposure to provide guidance on the optimal prescribing
patterns.
Clinical studies do not provide conclusive evidence of the
benefit of combination therapy in the treatment of infections with
the exception of tuberculosis and HIV [47]. In these cases,
combination therapy is effective due to the high bacterial burden
and high rate of emergence of resistance during therapy through
mutations [47]. For other bacteria is remains unclear from clinical
studies whether combination therapy provides a benefit in
reducing resistance. Thus, current guidelines for improving
antibiotic use from the Infectious Disease Society of America
and the Society for Healthcare Epidemiology do not recommend
use of combination therapy [47]. However, we would like to point
out that in clinical practice, when laboratory tests confirm the co-
existence of different antimicrobial-resistant bacteria with different
antimicrobial susceptibility profiles, combination therapy is used to
target each pathogen. In our paper, combination therapy referred
to the use of two antimicrobials both of which would have efficacy
against the infecting organism. In fact, our model supports the use
of combination therapy in preventing the emergence of multiple
resistant strains within an individual [10,11,19,22,48]. The effect
of widespread combination therapy on the emergence and spread
of resistant bacteria to other patients however was not addressed.
Future models should incorporate both individual- and population
level analysis to determine the impact of the spread of resistant
bacteria within a community or hospital setting.
For the purpose of numerical simulations, in Model (1) we
assumed that the growth of bacteria satisfies the specific logistic
equation and the immune response satisfies the specific Monod
function. It should be pointed out that Model (1) can be
generalized to include a general bacteria growth term g(B) and a
general immune response function p(B), where g(B) is continuously
differentiable and satisfies g(0)=g(K)=0 for a positive constant K,
and g9(0).0, g9(K),0. p(B) is also continuously differentiable and
satisfies p(B).0 and p9(B).0. Similar extensions apply to Models
(2) and (3).
Our conclusions were mainly based on the numerical
simulations of Models (1)–(3). It would be very interesting and
helpful to perform qualitative analysis of these models and provide
theoretical support for our numerical simulations and thus our
conclusions. Studies on the dynamics of these models are under
consideration and will be reported somewhere else.
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